Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics Inc    SRPT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Sarepta Therapeutics Inc : SRPT, FB, CRUS and OMER added to NASDAQ Active Stock Watch List at GSR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/24/2013 | 03:05pm CEST

New York, NY - (ACCESSWIRE) - 09/24/2013 - Growing Stock Report initiates its NASDAQ Active Stock Watch List adding Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Facebook, Inc. (NASDAQ:FB), Cirrus Logic Inc. (NASDAQ:CRUS), and Omeros Corporation (NASDAQ:OMER)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) a biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases closed up in its previous session (+10.79%) on 6,581,320 shares traded after Sarepta was upgraded to Overweight from Neutral at Piper Jaffray. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is currently up (+251.61%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=SRPT&SubId=AW

Facebook, Inc. (NASDAQ:FB) operates as a social networking company worldwide closed down in its previous session (-0.63%) on 75,274,915 shares traded after Facebook Quietly Rolls Out Its Mobile Payments Autofill Product, AllThingsD Reported. Facebook, Inc. (NASDAQ:FB) is currently down (-2.75%) from its recent 52-week high, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Facebook, Inc. (NASDAQ:FB)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=FB&SubId=AW

Cirrus Logic Inc. (NASDAQ:CRUS) a fabless semiconductor company that develops analog and mixed-signal integrated circuits for a range of consumer and industrial markets closed up in its previous session (+5.41%) on 6,219,309 shares traded after CIRRUS LOGIC INC Filed SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year. Cirrus Logic Inc. (NASDAQ:CRUS) is currently up (+46.96%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Cirrus Logic Inc. (NASDAQ:CRUS)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CRUS&SubId=AW

Omeros Corporation (NASDAQ:OMER) a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system closed up in its previous session (+28.21%) on 8,095,031 shares traded after Omeros has been Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference on Friday, September 27, 2013. Omeros Corporation (NASDAQ:OMER) is currently up (+167.95%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Omeros Corporation (NASDAQ:OMER)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=OMER&SubId=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
editor@GrowingStockReport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SAREPTA THERAPEUTICS INC
02:31p Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthe..
10:38a SAREPTA THERAPEUTICS : Shares Bought by Metropolitan Life Insurance Co. NY
03/18 SAREPTA THERAPEUTICS : Announces Presentations at the 2017 MDA Scientific Confer..
03/17 Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Confe..
03/09 SAREPTA THERAPEUTICS : Announces Fourth Quarter and Full-Year 2016 Financial Res..
03/03 SAREPTA THERAPEUTICS INC : Biotech's Outlook Strengthens After President Trump's..
03/03 Sarepta Therapeutics to Present Company Overview at the Cowen and Company 37t..
03/01 SAREPTA THERAPEUTICS : Management's Discussion and Analysis of Financial Conditi..
03/01 SAREPTA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Fina..
03/01 SAREPTA THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 563..
More news
Sector news : Bio Therapeutic Drugs
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/15 Better Out Than In As Pharma Continues To Find Value Externally
03/07 Santhera Pharmaceuticals establishes U.S. operations to advance DMD candidate..
03/06 FDA to review PTC's marketing application for DMD candidate Translarna under ..
03/02 Leerink likes Sarepta, sees 42% upside; shares up 10%
03/02 Premarket analyst action - healthcare
Advertisement
Financials ($)
Sales 2017 97,2 M
EBIT 2017 -141 M
Net income 2017 -144 M
Finance 2017 265 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 13,9x
EV / Sales 2018 6,08x
Capitalization 1 620 M
More Financials
Chart SAREPTA THERAPEUTICS INC
Duration : Period :
Sarepta Therapeutics Inc Technical Analysis Chart | SRPT | US8036071004 | 4-Traders
Full-screen chart
Technical analysis trends SAREPTA THERAPEUT...
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 62,2 $
Spread / Average Target 110%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Edward M. Kaye President, Chief Executive & Medical Officer
M. Kathleen Behrens Chairman
Sandesh Mahatme Chief Financial Officer & Senior Vice President
Hans Lennart Rudolf Wigzell Independent Director
Richard Jon Barry Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS I..7.73%1 620
AMGEN, INC.11.52%120 086
CELGENE CORPORATION7.21%96 538
GILEAD SCIENCES, INC.-6.07%87 925
REGENERON PHARMACEUTIC..7.37%41 811
ACTELION LTD24.44%30 002
More Results